Merck & Co. (MRK, Financial) experienced a notable stock movement with a 0.89% increase, trading at $100.02 per share. The trading volume reached 3.2 million shares, with a turnover rate of 0.13% and a price fluctuation of 1.58%. Recent financial reports show Merck's revenue at $16.715 billion, net profit at $3.157 billion, and earnings per share at $1.25. The company has a gross profit of $12.274 billion and a price-to-earnings ratio of 20.92.
Among 26 rating agencies, 69% recommend buying Merck's stock, while 31% suggest holding, with no sell recommendations. In the pharmaceutical industry, where Merck operates, there was an overall decline of 0.50%. Notable performers in the sector include Cyclo Therapeutics, Medicus Pharma, and Citius Oncology, with significant gains, while Cbdmd, Su Xuantang, and Nature's Medicine showed high activity levels.
Merck is known for its pharmaceuticals targeting cardiovascular, cancer, and infectious diseases. Its immuno-oncology platform is a significant sales contributor, alongside a robust vaccine portfolio, including hepatitis B, pediatric diseases, HPV, and shingles treatments. The company also has a strong animal health segment, with nearly half of its sales from the U.S.
Significant news impacting Merck includes the acquisition of an Irish vaccine plant from WuXi Biologics for approximately $500 million. This facility was initially built for Merck by WuXi Biologics in Ireland.
